The Board of Medicine, a nonprofit organization dedicated to creating evidence-based guidelines for emerging medical treatments and practices, has announced the launch of its Membership Program, designed to give healthcare professionals and the public expanded access to advanced research, educational resources, and professional training. The board brings together leading experts to explore treatments and therapies that often fall outside conventional medical institutions, including wearable health technology, plant-based medicines, psychedelic-assisted therapy, somatic therapies, and supplement optimization, making it the first organization to establish clinical guidelines in these areas.
Health Technology Insights: Allink Biotherapeutics Secures $47Million Series A Extension
Through its membership program, participants gain access to timely updates on medical innovations, expert-led webinars, publications, live events, professional training, and consultation opportunities. Members also receive priority access to new certifications, third-party testing discounts, and early participation in collaborative research initiatives. The program is structured across tiers ranging from $50 to $1,500 annually, providing flexibility while offering resources to help clinicians, students, and interested members stay current with advances in medicine, neuroscience, and technology-driven care.
Health Technology Insights: Cosette Pharma Launches First Generic CIPRO HC with CGT Exclusivity
Dr. Dave Rabin, MD, PhD, board-certified psychiatrist, neuroscientist, and Executive Director of The Board of Medicine, explained that the organization exists to protect patients’ rights to access the most effective treatments, even when traditional regulations lag behind. He added that members benefit from exposure to cutting-edge research and advanced educational resources that allow them to understand and apply the latest scientific and clinical developments.
The board’s research integrates precision medicine, preventive care, and technology into clinical practice, using metrics such as heart rate variability and vagal tone to predict patient response to different treatments. This approach aims to improve personalized care, optimize outcomes, and inform healthcare decision-making for patients and providers alike.
Since its founding in 2019, The Board of Medicine has published peer-reviewed studies on emerging therapies, including psychedelic-assisted treatment for PTSD, frameworks for cannabinoid use in harm reduction, and best practices for novel medical approaches. With the launch of this membership program, the board seeks to engage a broader audience in shaping the standards of care for modern medical treatments while providing education and resources to advance clinical knowledge and patient-centered care worldwide.
Health Technology Insights: Victor Miller Joins NorthStar Medical Radioisotopes, LLC as Chief Financial Officer
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
